Literature DB >> 15097858

Pancreatic enzyme extract improves survival in murine pancreatic cancer.

Murat Saruc1, Silke Standop, Jens Standop, Fumiaki Nozawa, Atsushi Itami, Krishan K Pandey, Surinder K Batra, Nicholas J Gonzalez, Pierre Guesry, Parviz M Pour.   

Abstract

OBJECTIVES: The disappointing current therapeutic approaches for pancreatic cancer (PC) represent an urgent need for the development of novel methods to control the disease. Based on a recent report on the effectiveness of pancreatic enzyme therapy, we examined the effect of porcine pancreatic enzyme extracts (PPE) on human PC xenografts in nude mice.
METHODS: The malignant human PC cell line AsPC1 was transplanted into the pancreas of male beige XID nude mice that were treated or not with PPE in drinking water. The survival, size, and volume of tumors, plasma pancreatic enzyme levels, fecal fat, and urine were examined as were the expression of transforming growth factor alpha, insulinlike growth factor-I, epidermal growth factor, epidermal growth factor receptor, apoptosis, and proliferation rate of tumor cells.
RESULTS: PPE-treated mice survived significantly longer than the control group (P < 0.002). Tumors in the PPE-treated group were significantly smaller than in the control group. All mice in the control group showed steatorrhea, hyperglucosuria, hyperbilirubinuria, and ketonuria at early stages of tumor growth, whereas only a few in the treated group showed some of these abnormalities at the final stage. There were no differences in the expression of growth factors, epidermal growth factor receptor, or the apoptotic rate between the tumors of treated and control mice.
CONCLUSIONS: The treatment with PPE significantly prolongs the survival of mice with human PC xenografts and slows the tumor growth. The data indicate that the beneficial effect of PPE on survival is primarily related to the nutritional advantage of the treated mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15097858     DOI: 10.1097/00006676-200405000-00009

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Research Battles: Survival Tips From a Veteran.

Authors:  Linda L Isaacs
Journal:  Integr Med (Encinitas)       Date:  2015-10

2.  Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Authors:  Murielle Mimeault; Sonny L Johansson; Jean-Pierre Henichart; Patrick Depreux; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-02-23       Impact factor: 6.261

Review 3.  Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action.

Authors:  Hari Sharan Adhikari; Paras Nath Yadav
Journal:  Int J Biomater       Date:  2018-12-30

Review 4.  Pancreatic Proteolytic Enzymes and Cancer: New Support for an Old Theory.

Authors:  Linda L Isaacs
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

5.  A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer.

Authors:  Macarena Perán; Elena López-Ruiz; María Ángel García; Shorena Nadaraia-Hoke; Ralf Brandt; Juan A Marchal; Julian Kenyon
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

6.  Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting.

Authors:  Pablo Hernández-Camarero; Elena López-Ruiz; Carmen Griñán-Lisón; María Ángel García; Carlos Chocarro-Wrona; Juan Antonio Marchal; Julian Kenyon; Macarena Perán
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.